KEY INFORMATION DOCUMENT

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

PRODUCT

Oncology, R - Capitalisation, a sub-fund of Candriam Equities L, SICAV

Manufacturer:	Candriam, a New York Life Investments group entity.
ISIN:	LU1864483166
Website:	www.candriam.com
Contact:	Call +352 27 97 24 25 for more information
Competent Authority:	The Commission de Surveillance du Secteur Financier (CSSF) is in charge of the control of Candriam with regard to this key information document. . This product is authorised in Luxembourg. Candriam is approved in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

This key information document is valid as at 2026-01-01.

WHAT IS THIS PRODUCT?

Type: This product is a share class (R) of a sub-fund (Oncology) of an investment company with variable capital (SICAV) under Luxembourg law (Candriam Equities L), Undertakings for Collective Investment in Transferable Securities (UCITS).

Term: Open-ended.

Objectives:

Principal assets traded:
Equities of companies in the field of oncology (cancer research, diagnosis, treatment, etc.) whose registered offices and/or principal activities are throughout the world.
Investment strategy:
The fund seeks to achieve capital growth by investing in the principal assets traded and to outperform the benchmark while also generating a positive social impact over the long term, by selecting companies that address certain societal challenges and mobilise resources in the fight against cancer.
The management team makes discretionary investment choices based on economic/financial analyses, but also on the basis of Candriam's internal analysis of environmental, social and governance (ESG) criteria.
There are several strands in the selection of securities: a thematic filter, a clinical analysis and a fundamental analysis.
The thematic filter only accepts companies with a sufficient exposure to oncology and the battle against cancer in general, for example in areas such as treatments, diagnostic tools, medical equipment and services, and dedicated technologies.
The clinical analysis aims to assess the quality of the available clinical data and to use only companies found to be convincing in this respect.
The fundamental analysis focuses on those companies scoring the highest in five criteria: quality of management, growth potential, competitive advantage, value creation and indebtedness.
To achieve its social objective, the fund seeks to outperform the benchmark in two social indicators (i) research and development spending as a proportion of the company's market capitalisation and (ii) the level of education of management teams, measured as the percentage of senior executives holding a doctorate, with the aim of evaluating the human and financial resources mobilised by the companies in the battle against cancer.
The issuers are evaluated on the basis of an analysis of their activities (to assess how their activities relate to the battle against cancer) and stakeholders (how the companies manage the main considerations concerning stakeholders such as human resources, the environment, etc.).
In particular, the fund aims not to select companies with the lowest ESG scores, and to focus the investments on companies which deliver solutions in the field of oncology. The analysis of ESG aspects is therefore included in the selection, analysis and global evaluation of companies. The fund also aims to exclude investments in companies which do not respect certain recognised international standards and principles, or which are significantly exposed to certain controversial activities, or which work with countries considered to be the most oppressive. The analysis of ESG aspects depends on the availability, quality and reliability of the underlying data. It is therefore possible that the management teams is unable to select a company with an attractive financial valuation. The analysis and selection process is also accompanied by active involvement, in particular dialogue with companies and voting as the shareholder at AGMs. For more information, please see the management company's website and/or the prospectus.
The fund may make use of derivative products for both investment and hedging purposes (to protect against future unfavourable financial events).
Benchmark: MSCI World Health Care Index (Net Return).
The fund is managed actively and the investment approach implies a reference to a benchmark (the index).
Benchmark definition:
The index measures the performance of the large and mid capitalisation equity segment across developed markets countries.
Use of the benchmark:
- as an investment universe. In general, the financial instruments of the sub-fund are mostly contained in the index. However, investments outside this index are authorised;
- in determining risk levels/parameters.

As the fund is managed actively, it does not aim to invest in each component of the index nor to invest in the same proportions as the components of the index. In normal market conditions, the expected tracking error of the fund will be large, i.e. above 4%. This measure is an estimation of the divergence of the fund's performance compared to the performance of the benchmark. The greater the tracking error, the greater the deviations from the index. The actual tracking error depends in particular on market conditions (volatility and correlations between financial instruments) and may therefore differ from the expected tracking error.
Repayment of shares: On demand, every day, at Luxembourg.
Allocation of income: Reinvestment.

Intended retail investor:

This product is for investors who meet the conditions for accessing the product in question (see prospectus) with any level of knowledge and experience who are looking for Capital Growth. This product can be used as a core holding or a component of a diversified portfolio for investments with an investment horizon of 6 years. Investors should understand the product risks and only invest if they can bear potentially substantial losses.

General information:

Depositary bank: CACEIS Bank, Luxembourg Branch.

Other information:
This document provides a description of a share class of a sub-fund of Candriam Equities L. The prospectus and periodical reports are established for all the sub-funds. There are other share classes and these are listed in the prospectus.
Investors may apply for the conversion of their shares into shares of another class of the same sub-fund or into shares of a class of another sub-fund of the fund, based on the eligibility criteria and following the procedures available through their financial intermediary.
The sub-fund is only liable for the debts, liabilities and obligations that can be charged to it.
Additional information about the fund can be found in the prospectus and the periodical reports, which may be obtained free of charge on request from Candriam or viewed at any time on the website www.candriam.com. These documents are available in one of the languages approved by the local authority of each country where the fund is authorised to market its shares or in a common language in the international finance sphere. All other practical information, in particular the latest share price, is available from the places shown above.

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

1	2	3	**4**	5	6	7

Lower risk — Higher risk

The risk indicator assumes you keep the product for 6 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

Risk Indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as class 4 out of 7, which is a medium risk class.

This rates the potential losses from future performance at a medium level, and poor market conditions could impact the capacity to pay you.

Be aware of the currency risk. If your reference currency is different from the product's currency, the yield of your investment will also be influenced by fluctuations, both up and down, in the exchange rate between these two currencies. In this case, the risk indicator above does not in fact take account of the fluctuations between these two currencies.
Other risk(s) materially relevant not included in the summary risk indicator: Derivatives. Emerging markets. Liquidity. Concentration.

This product does not include any protection from future market performance so you could lose some or all of your investment.

Performance scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your adviser or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and/or a suitable benchmark over the last 11 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.
Unfavourable: This type of scenario occurred for an investment between 12/2022 and 01/2025.
Moderate: This type of scenario occurred for an investment between 02/2016 and 01/2022.
Favourable: This type of scenario occurred for an investment between 06/2014 and 05/2020.

Recommended holding period: **Example Investment:**		**6 years** **10 000 EUR**	
		If you exit after 1 year	**If you exit after 6 years**
Scenarios			
Minimum	**There is no minimum guaranteed return. You could lose some or all of your investment.**		
Stress	***What you might get back after costs***	**2 010 EUR**	**3 410 EUR**
	Average return each year	- 79.87%	- 16.41%
Unfavourable	***What you might get back after costs***	**8 080 EUR**	**9 620 EUR**
	Average return each year	- 19.16%	- 0.64%
Moderate	***What you might get back after costs***	**10 670 EUR**	**20 910 EUR**
	Average return each year	6.69%	13.08%
Favourable	***What you might get back after costs***	**14 970 EUR**	**25 590 EUR**
	Average return each year	49.74%	16.95%

WHAT HAPPENS IF CANDRIAM IS UNABLE TO PAY OUT?

As the Funds' assets are held with the depositary, they are not part of the assets of Candriam in case of bankruptcy and cannot be seized by the creditors of Candriam. Nevertheless, investors run the risk to suffer a financial loss in case of the default of Candriam.

In case of default of the depositary, the risk of a financial loss is mitigated to some extend as the Fund's assets are legally segregated from the assets of the depositary.

The potential financial loss associated with the default of Candriam is not covered by an investor compensation or guarantee scheme.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- EUR 10 000 is invested.

	If you exit after 1 year	If you exit after 6 years
Total costs	**501 EUR**	**2 553 EUR**
Annual cost impact (*)	5.0%	2.2% each year

* This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 15.3% before costs and 13.1% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

If the fund is part of another product, such as an insurance product, the costs shown here do not include any additional costs you may incur.

Composition of Costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	3.50% maximum of the amount you pay in when entering this investment.	Maximum 350 EUR
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0 EUR
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.11% of the value of your investment per year. This is an estimate based on actual costs over the last year.	130 EUR
Transaction costs	0.21% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	21 EUR
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	N/A

Switch fee (Max.): 0.00%. For more information about how to exercise that right, see section "General information" and/or refer to the prospectus.

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MONEY OUT EARLY?

Recommended holding period: **6 years**

The choice of recommended holding period depends on the types of the underlying investments and on the associated degree of risk, which may be higher or lower. For example “equity” type products (higher risk) generally have a recommended holding period of six years (long term), and “bonds or money market” type products (lower risk) have a shorter recommended holding period (generally between two and four years for bond products or less than one year for money market products - medium term/short term). “Mixed” type products generally have a recommended holding period of between three and five years depending on the weighting of the types of underlyings. “Alternative” type products generally have a recommended holding period of three years.

Investors may request redemption of their units at any time under the conditions set out in “What will this investment cost me? ”. The shorter the holding period in relation to the recommended period, the greater the potential impact of any charges on the performance profile.

HOW CAN I COMPLAIN?

Complaints about this product or about the conduct of the product manufacturer or the person advising on, or selling, the product:

Postal address:	Candriam, SERENITY – Bloc B, 19-21, route d’Arlon – L-8009 Strassen
Website:	https:\\contact.candriam.com
E-mail:	complaints@candriam.com

OTHER RELEVANT INFORMATION

Alongside with this document, please read the prospectus on the website www.candriam.com.

The past performance of this product for 6 years can be accessed via the following link: https://www.candriam.com/documents/redirect/Candriam/KPP/fr/LU1864483166. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. However, it can help you to assess how the fund has been managed in the past.

Past performance scenario calculations are available via the following link: https://www.candriam.com/documents/redirect/Candriam/KMS/fr/LU1864483166.

Details of the up-to-date remuneration policy, including the composition of the remuneration committee and an overview of how remuneration and benefits are determined, are available on the website https://www.candriam.com/siteassets/legal-and-disclaimer/external_disclosure_remuneration_policy.pdf.

Upon request, a paper copy of the remuneration policy can be obtained from the Management Company free of charge.